Physician profile
Sujit Sheth
NPI 1841263878
$358,718.06
in general payments reported to CMS, 2019-2025
17 companies · $84K in 2025
The $84K reported for 2025 was more than what 98% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $41K · 2021: $16K · 2022: $45K · 2023: $51K · 2024: $81K · 2025: $84K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $134K · Travel and Lodging: $51K · Honoraria: $24K · Food and Beverage: $4,446 · Grant: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $133,868.19 |
| Travel and Lodging | $51,233.51 |
| Honoraria | $23,829.16 |
| Food and Beverage | $4,445.74 |
| Grant | $2,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $135,981.43 | 2019-2025 | Pyrukynd |
| Celgene Corporation | $80,187.20 | 2019-2025 | |
| Vertex Pharmaceuticals Incorporated | $75,837.74 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $32,239.32 | 2022-2024 | Reblozyl |
| Chiesi USA, INC. | $17,374.83 | 2020-2025 | Ferriprox |
| Novo Nordisk Health Care Ag | $7,652.75 | 2024-2025 | |
| Acceleron Pharma, INC. | $5,940.00 | 2020 | |
| Octapharma USA, INC. | $2,500.00 | 2024 | Nuwiq |
| Mckesson Corporation | $530.00 | 2022 | |
| Genentech USA, INC. | $349.79 | 2021-2023 | |
| Apo-Pharma INC. | $125.00 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujit Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.